98%
921
2 minutes
20
Introduction: Frequent HIV testing of at-risk individuals is crucial to detect and treat infections early and prevent transmissions. We assessed the effect of reminders on HIV retesting uptake.
Methods: The study was conducted within a programme involving four facilities providing free-of-charge HIV, syphilis and hepatitis B and C testing and counselling in northern Thailand. Individuals found HIV negative and identified at risk by counsellors were invited to participate in a three-arm, open-label, randomized, controlled trial comparing: (a) "No Appointment & No Reminder" (control arm); (b) "No Appointment but Reminder": short message service (SMS) sent 24 weeks after the enrolment visit to remind booking an appointment, and sent again one week later if no appointment was booked; and (c) "Appointment & Reminder": appointment scheduled during the enrolment visit and SMS sent one week before appointment to ask for confirmation; if no response: single call made within one business day. The primary endpoint was a HIV retest within seven months after the enrolment visit. The cost of each reminder strategy was calculated as the sum of the following costs in United States dollars (USD): time spent by participants, counsellors and hotline staff; phone calls made; and SMS sent. The target sample size was 217 participants per arm (651 overall).
Results: Between April and November 2017, 651 participants were randomized. The proportion presenting for HIV retesting within seven months was 11.2% (24/215) in the control arm, versus 19.3% (42/218) in "No Appointment but Reminder" (p = 0.023) and 36.7% (80/218) in "Appointment & Reminder" (p < 0.001). Differences in proportions compared to the control arm were respectively +8.1% (95% CI: +1.4% to +14.8%) and +25.5% (+17.9% to +33.2%). The incremental cost-effectiveness ratios of "No Appointment but Reminder" and "Appointment & Reminder" compared to the control arm were respectively USD 0.05 and USD 0.14 per participant for each 5% increase in HIV retesting uptake within seven months.
Conclusions: Scheduling an appointment and sending a reminder one week before was a simple, easy-to-implement and affordable intervention that significantly increased HIV retesting uptake in these at-risk individuals. The personal phone call to clients probably contributed, and also improved service efficiency.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159062 | PMC |
http://dx.doi.org/10.1002/jia2.25478 | DOI Listing |
Sex Transm Infect
August 2025
Melbourne Sexual Health Centre, Carlton, Victoria, Australia.
Background: Syphilis infections are rising in many countries. Syphilis reinfections can occur among patients with ongoing risk. We aimed to describe the characteristics of syphilis reinfections and the interval time between syphilis reinfections.
View Article and Find Full Text PDFLancet HIV
September 2025
SHARE Collaborative, Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UK.
Background: Definitions of virological failure and treatment discontinuation for long-acting injectable (LAI) cabotegravir and rilpivirine antiretroviral therapy are inconsistent in clinical practice and observational studies, which complicates interpretation and implementation of findings. The CONSENSUS-LAI study aimed to establish consistent definitions of virological failure and treatment discontinuation to enhance evidence transferability and support optimal clinical outcomes.
Methods: The study had two phases.
Sci Rep
August 2025
Medical Research Council, University of Glasgow Centre for Virus Research, Glasgow, UK.
Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus (HCV) neutralisation in people living with HIV. SARS-CoV-2 neutralisation was assessed using HIV-based SARS-CoV-2 pseudoviruses in sera from a longitudinal Malawian cohort (n = 1,876), detecting neutralisation across timepoints in 10.
View Article and Find Full Text PDFBMC Public Health
July 2025
Department of Nursing, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Objective: To develop a culturally adapted scale measuring HIV-related irrational beliefs among PLHIV in China, and to examine its psychometric properties.
Methods: The study was conducted from 05/2022 to 11/2023 with four stages. Stage 1: a pool of items was constructed through semi-structured interviews with 48 PLHIV; Stage 2: 14 multidisciplinary experts were invited to evaluate the content validity of the scale; Stage 3: the test-retest reliability of the scale was conducted with 31 PLHIV; and Stage 4: a convenience sampling was used to conduct an online and on-site survey of PLHIV in eight designated institutions of antiretroviral treatment in Luzhou and Anyue regions.
Int J STD AIDS
June 2025
The Health Research Unit Zimbabwe, Biomedical Research and Training Institute, Harare, Zimbabwe.
BackgroundThe scale-up of antiretroviral therapy (ART) has enabled more children living with HIV to reach adolescence and become sexually active. We investigated pregnancy incidence and outcomes among adolescents with perinatally acquired HIV enrolled in a multi-country trial of vitamin D and calcium carbonate supplementation (VITALITY; PACTR202009897660297).MethodsBetween February and November 2021, 842 adolescents aged 11-19 years from Zambia and Zimbabwe on ART for at least 6 months were enrolled.
View Article and Find Full Text PDF